NovoCure Ltd. (NVCR) PT Raised to $250 at Northland Capital Markets
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
Northland Capital Markets analyst Jason Wittes raised the price target on NovoCure Ltd. (NASDAQ: NVCR) to $250.00 (from $200.00) while maintaining an Outperform rating.
The analyst commented, "Yesterday NVCR announced that following pre-specified annual review by the independent Data Monitoring Committee (DMC) for the Phase 3 pivotal LUNAR trial (Optune/TTF fields in stage 4 non-small cell lung cancer (NSCLC) following platinum failure) is recommended accelerating the trial. This was based on the length of accrual and the number of events observed in the 210 patients enrolled through February."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Accenture plc (ACN) PT Raised to $342 at Stifel
- Shenzhen Inovance Tech (300124:CH) PT Raised to RMB60 at Morgan Stanley
- China Telecom Corp. (728:HK) (CHA) PT Raised to HK$3.80 at Morgan Stanley
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst PT Change
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!